Main content area

Antibody responses following administration of a Cryptosporidium parvum rCP15/60 vaccine to pregnant cattle

Burton, A.J., Nydam, D.V., Jones, G., Zambriski, J.A., Linden, T.C., Cox, G., Davis, R., Brown, A., Bowman, D.D.
Veterinary parasitology 2011 v.175 no.1-2 pp. 178-181
Cryptosporidium parvum, absorption, antibodies, calves, colostrum, cows, cryptosporidiosis, dairies, developmental stages, diarrhea, drug therapy, gastroenteritis, pathogens, surface proteins, vaccine development
Cryptosporidium parvum is a zoonotic Apicomplexa-protozoan pathogen that causes gastroenteritis and diarrhea in mammals worldwide. Globally, C. parvum is ubiquitous on dairy operations and is the pathogen most commonly diagnosed in association with calf diarrhea. Here, we describe the antibody response in 20 pregnant cows to a recombinant C. parvum oocyst surface protein (rCP15/60) vaccine compared with 20 controls, and the antibody response in 19 calves fed the rCP15/60-immune colostrum from these vaccinated cows compared with 20 control calves. Cows vaccinated with rCP15/60 produced a significantly greater antibody response compared to controls (p<0.0001) and this response was strongly associated with the subsequent level of colostral antibody (r=0.82, p<0.0001). Calves fed rCP15/60-immune colostrum showed a dose-dependent absorption of antibody, also associated with colostral antibody levels (r=0.83, p<0.0001). Currently, drug therapy against cryptosporidiosis is limited making development of an effective vaccine attractive. This report describes the first stages in development of a C. parvum rCP15/60 vaccine designed to confer passive protection to calves against cryptosporidiosis.